NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Contingent Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Contingent Liabilities | ₹0.44 Cr | ₹0.10 Cr | ₹0.28 Cr | ₹0.28 Cr | ₹0.30 Cr |
What is the latest Contingent Liabilities ratio of NGL FINECHEM ?
Year | Contingent Liabilities |
---|---|
Mar2024 | ₹0.44 Cr |
Mar2023 | ₹0.10 Cr |
Mar2022 | ₹0.28 Cr |
Mar2021 | ₹0.28 Cr |
Mar2020 | ₹0.30 Cr |
How is Contingent Liabilities of NGL FINECHEM Trending?
Years | Contingent Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹0.44 Cr | 336.63 | |
Mar2023 | ₹0.10 Cr | -63.67 | |
Mar2022 | ₹0.28 Cr | 0.00 | |
Mar2021 | ₹0.28 Cr | -6.40 | |
Mar2020 | ₹0.30 Cr | - |
Compare Contingent Liabilities of peers of NGL FINECHEM
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
NGL FINECHEM | ₹654.0 Cr | -2.3% | -8.9% | -52.7% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹420,136.0 Cr | 6% | 4% | 9.9% | Stock Analytics | |
DIVIS LABORATORIES | ₹149,680.0 Cr | 4.7% | 0.3% | 52.4% | Stock Analytics | |
CIPLA | ₹122,390.0 Cr | 7% | 3.7% | 7.2% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹110,159.0 Cr | 4.1% | 6.4% | 25% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹97,105.6 Cr | 6.3% | 5% | -4.7% | Stock Analytics |
NGL FINECHEM Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
NGL FINECHEM | -2.3% |
-8.9% |
-52.7% |
SENSEX | 5.8% |
6.1% |
4.7% |
You may also like the below Video Courses